Explore 3 Stock Ideas & Industry Insights Download Free Report

Biostax Corp.

Company price
0.0002 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
2194
Market Cap
0.01M

Momentum Score

…

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biostax Corp. (OTC Pink: BTAX) is a U.S.-listed microcap with sparse public disclosures and no clear description of core operations or revenue streams. Long-term growth drivers are not identifiable from available material; the company could benefit if it later reports credible operational, regulatory, or financial milestones that support reassessment.
Key risks are minimal disclosure, low liquidity tied to an OTC Pink listing and the attendant uncertainty that material operating or financial information may be unavailable to investors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
1.10M
ROCE
48.46%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -2.36M -3.54M 3.59M 1.59M -3.40M
Minority interest - - - - 0.00M
Net income -2.36M -3.54M 3.59M 1.59M -3.40M
Selling general administrative 0.96M 1.15M 0.59M 0.76M 2.50M
Gross profit 0.00M 0.00M 0.00M 0.00M 0.00M
Reconciled depreciation 0.05M - 0.00M 0.00M 0.00M
Ebit -2.19M -1.16M -0.74M -0.89M -2.84M
Ebitda -2.14M - - - -
Depreciation and amortization 0.05M - - - -
Operating income -1.48M -1.16M -0.74M -0.89M -2.84M
Other operating expenses 1.48M - - - -
Interest expense 0.17M 0.12M 0.21M 0.48M 0.89M
Net interest income -0.17M -0.12M -0.21M -0.65M -0.89M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.48M 1.16M 0.74M 0.89M 2.84M
Cost of revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total other income expense net -0.88M -2.25M 4.54M 3.13M 0.34M
Net income from continuing ops -2.36M -3.54M 3.59M 1.59M -3.40M
Net income applicable to common shares - -3.54M 3.59M 1.59M -3.40M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.04M 0.96M 3.14M 0.01M 0.01M
Intangible assets 0.71M 0.76M - - -
Total liab 4.56M 3.48M 11.09M 11.68M 13.69M
Total stockholder equity -4.53M -2.51M -7.95M -11.67M -13.69M
Other current liab 0.09M 0.94M 0.89M 1.51M 0.85M
Common stock - 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -385.33M -382.97M -379.43M -383.02M -384.61M
Other assets - 0.05M - 0.00M 0.00M
Cash 0.03M 0.15M 0.49M 0.01M 0.00M
Total current liabilities 4.56M 3.48M 11.09M 11.68M 13.69M
Net debt 1.10M 0.55M 2.58M 2.83M 5.54M
Short long term debt 1.13M 0.70M 3.07M 2.84M 5.55M
Other stockholder equity - 0.01M 0.01M 0.01M 0.01M
Property plant equipment - - - - 0.00M
Total current assets 0.03M 0.15M 3.14M 0.01M 0.00M
Net tangible assets - -3.28M -7.95M -11.67M -13.69M
Short term investments 0.00M 0.00M 2.65M - -
Inventory - - - - 0.00M
Accounts payable 1.21M 1.30M 2.18M 2.56M 2.66M
Non current assets total 0.01M 0.81M 0.00M 0.00M 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00M -0.50M 0.00M - 0.00M
Change to liabilities - 0.39M 0.10M 0.10M 0.89M
Total cashflows from investing activities - -0.50M -0.50M -0.50M -0.50M
Net borrowings 0.14M 0.74M 0.72M 0.20M 0.20M
Total cash from financing activities 0.29M 0.74M 0.72M 0.20M 0.20M
Change to operating activities - 0.31M 0.58M 0.91M 2.40M
Net income -2.36M -3.54M 3.59M 1.59M -3.40M
Change in cash -0.12M -0.34M 0.48M 0.01M -0.00M
Begin period cash flow 0.15M 0.49M 0.01M 0.00M 0.01M
End period cash flow 0.03M 0.15M 0.49M 0.01M 0.00M
Total cash from operating activities -0.41M -0.58M -0.23M -0.19M -0.00M
Issuance of capital stock - - - - 0.00M
Depreciation 0.05M - 0.00M 0.00M 0.00M
Change to inventory - - - 0.00M 0.08M
Other cashflows from financing activities 0.15M - - - -
Change to netincome - 2.25M -4.54M -2.96M -0.20M
Capital expenditures 0.00M 0.50M 0.00M 0.00M 0.00M
Change in working capital 0.85M 0.70M 0.68M 1.01M 3.35M
Other non cash items 1.05M -3.17M 0.03M -3.17M 0.38M
Free cash flow -0.41M -1.08M -0.23M -0.19M -0.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BTAX
Biostax Corp.
-
-%
0.00 - - - - 268.58 -16.41
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Biostax Corp.

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.

2431 Aloma Ave., Winter Park, FL, United States, 32804

888 613 8802

Name Title Year Born
Ms. Noreen M. Griffin Founder, Executive VP of Business Development & CEO 1953
Ms. Kelly O'Brien Wilson President 1971
Mr. Glen A. Farmer M.B.A. Chief Financial Officer 1969
Mr. Robert Wilson VP of Strategy & Director 1973
Ms. Cynthia Douglas Company Secretary 1973
Dr. Joseph M. Fortunak Vice President of Global Research & Development and Chemical Development 1955
Ms. Kelly O'Brien Wilson President 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…